ODESSA, Texas (KMID/KPEJ) – Dr. Manohar Angirekula, Dr. Adam Farber, and Dr. Fernando Boccalandro have successfully implanted the first “Watchman FLX” Pro Device at Medical Center Hospital.

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...

The staff at Shasta Regional Medical Center (SRMC) is celebrating their 100th Watchman heart implant procedure, which took ...

5.0%). The OPTION trial included 1,600 patients. In the trial, approximately 60% of device patients had their WATCHMAN FLX ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

In the trial, approximately 60% of device patients had their WATCHMAN FLX implant 90-180 days following their ablation procedure. The other nearly 40% of the device patients had the two procedures ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.